AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06665906 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Web-Based Cognitive Behavioral Therapy (PainTrainer)
Description: Self-guided program that contains 8 modules, lasting 30-40 minutes each and can be completed in 8 to 12 weeks. Each module teaches behavioral coping strategies for pain management and recommends practice exercises.
Study NCT06665906 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Intervention
Description: At least six phone call visits, plus or minus 4, with patient navigator to coordinate care.
Study NCT05184075 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard hybrid coronary revascularization
Description: Patients will undergo endoscopic coronary artery bypass grafting (endo-CABG) within four weeks after the diagnostic coronarography. Furthermore, they will receive a percutaneous coronary intervention (PCI) within four weeks after the endo-CABG.
Study NCT05184075 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Reverse hybrid coronary revascularization
Description: Patients will receive a percutaneous coronary intervention (PCI) within four weeks after the diagnostic coronarography. Furthermore, they will undergo the endoscopic coronary artery bypass grafting (endo-CABG) within four weeks after the PCI.
Study NCT06084013 — intervention group
Intervention type: OTHER
Intervention: Non-Interventional Study
Description: Non-interventional study
Study NCT04926831 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capmatinib
Description: 150 mg and 200 mg tablets for oral administration
Study NCT05427994 — intervention group
Intervention type: OTHER
Intervention: National Eye Institute Visual Function Questionnaire
Description: National Eye Institute Visual Function Questionnaire (NEI-VFQ-25) measures the quality of life related to vision. This questionnaire has been validated for use on low vision patients.
Study NCT06517212 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirzepatide
Description: Patients will receive tirzepatide once weekly for up to 2 years.
Study NCT05426096 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best Practice Advisory
Description: The BPA intervention will test the delivery of the insulin calculator (BPA) which automates the standard insulin dosing protocol guidelines through the electronic health record system.
Study NCT06677866 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy
Description: Cooperative Group Therapy (CGT) is a cognitive-behavioral group therapy based on the theoretical and practical principles of the Cooperative Parent-Mediated Therapy model \[Valeri et al., 2020\].~The goal of CGT is to promote the following core skills: Pragmatics, Executive Functions, and Cooperative Interactions. The CGT program consists of 15 sessions over a total duration of 6 months: 12 group therapy sessions with adolescents and 3 sessions with their parents. Each session focuses on a specific topic and lasts between 90 and 120 minutes.~The CGT therapist is a psychotherapist with a cognitive-behavioral orientation who utilizes evidence.-based strategies to enhance pragmatic, socio-conversational skills, cognitive flexibility, emotional regulation, and cooperative interactions. The CGT intervention is conducted by two cognitive-behavioral psychotherapists specialized respectively in the treatment of FXS and ASD.
Study NCT06677866 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Waiting List
Description: The Waiting List (WL) is a control group in which participants who do not receive the experimental treatment are placed on a waiting list to receive the intervention after the active treatment group has completed it. In the case of the WL, the CGT intervention is carried out after at least 6 months to allow the patients in the first group to complete the treatment cycle. This approach enables a comparison between a group of treated patients and a group of patients who have not yet been treated, while still allowing the latter to access the treatment at a later stage.
Study NCT06679075 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Full pulpotomy using propolis and bioceramic putty
Description: Full Pulpotomy for participants with mature adult molars diagnosed with irreversible pulpitis; using Propolis as a hemostatic agent and bioceramic putty as a dressing material
Study NCT06679075 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Full pulpotomy using Propolis and MTA
Description: Full Pulpotomy for participants with mature adult molars diagnosed with irreversible pulpitis; using Propolis as a hemostatic agent and MTA as a dressing material
Study NCT06679075 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Full pulpotomy using sodium hypochlorite and bioceramic putty
Description: Full Pulpotomy for participants with mature adult molars diagnosed with irreversible pulpitis; using sodium hypochlorite (NaOCl) as a hemostatic agent and bioceramic putty as a dressing material
Study NCT06679075 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Full pulpotomy using sodium hypochlorite and MTA
Description: Full Pulpotomy for participants with mature adult molars diagnosed with irreversible pulpitis; using sodium hypochlorite (NaOCl) as a hemostatic agent and MTA as a dressing material.
Study NCT06680284 — intervention group
Intervention type: OTHER
Intervention: Staff Education Program
Description: A staff education and environmental awareness campaign and in-service to highlight strategies to reduce, reuse, and recycle waste, as well as proper waste disposal practice, will be implemented by way of instructional posters, e-learning modules, a grand rounds presentation, journal club discussion, and brainstorming sessions for waste reduction, reuse and recycle and a brief knowledge test at the end.
Study NCT06681636 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human papillomavirus 9-valent vaccine, Recombinant
Description: HPV vaccine manufactured by MSD consisted of 9HPV types: 6,11,16,18,31,33, 45, 52,58
Study NCT06681636 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Human papillomavirus 9-valent vaccine, Recombinant
Description: HPV vaccine manufactured by MSD consisted of 9HPV types: 6,11,16,18,31,33, 45, 52,58
Study NCT05136690 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine patch
Description: Nicotine 21 mg transdermal nicotine patch.
Study NCT05669027 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neurofeedback
Description: Participants will be asked to complete 10-minute sessions at least 4 days per week for 12 weeks. Participants will be asked to report their current level of pain, stress, and anger before and after each session. The experimental condition involves a mobile app that provides auditory feedback signaling EEG alpha power above a threshold level, denoting a physiologically relaxed state.
Study NCT05669027 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham (Placebo Control)
Description: Participants will be asked to complete 10-minute sessions at least 4 days per week for 12 weeks. Participants will be asked to report their current level of pain, stress, and anger before and after each session. The control condition involves a visually identical mobile app yoked to a pre-recorded set of actual neurofeedback sessions (i.e., placebo).
Study NCT05136690 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-4334
Description: MK-4334 250 mg capsule taken by mouth.
Study NCT05136690 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo patch
Description: Placebo patch.
Study NCT05136690 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo capsule
Description: Placebo capsule taken by mouth.
Study NCT06680856 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: PRP+HA
Description: treatment of diabetic foot ulcers with allogeneic PRP+HA
Study NCT06680856 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: HA
Description: treatment of diabetic foot ulcers with HA
Study NCT06680193 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Processing of Positive Memories Technique
Description: PPMT was administered weekly as a 4-session protocol. In session 1, participants receive psychoeducation on PTSD symptoms, an overview of PPMT, and are assessed for psychological symptoms. Sessions 1-4 involve the detailed processing of a salient positive autobiographical memory to elicit values, affect, strengths, and thoughts related to that positive memory. Homework assignments include listening to an audio recording of that memory, completing a values, affect, strengths, and thoughts log, and engaging in a behavioral activity. In session 4, the therapist also reviews psychological symptoms and addresses termination.
Study NCT05830084 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: regorafenib tablet
Description: Regorafenib will be escalated/de-escalated, starting at DL0:~* DL1: 82 mg/m\^2 once daily for 21 days/28 days (max 160mg) (100% of the RP2D)~* DL0 (starting dose): 66 mg/m\^2 once daily for 21 days/28 days (max 120mg) (80% of the RP2D)~* DL-1: 50 mg/m\^2 once daily for 21 days/28 days (max 80mg) (60% of the RP2D)
Study NCT06679829 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Siltuximab
Description: 11 mg/kg, will be administered seven days before and 14 days after autologous hematopoietic stem cell infusion (+/-2 day).
Study NCT06679829 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Arm A: 70mg/m2 of melphalan on Day -2.~Arm B: SOC BSA based melphalan dosing at 140 or 200mg/m2 per treating physician on Day -2
Study NCT06679829 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melphalan
Description: Arm A: 70mg/m2 of melphalan on Day -2.~Arm B: SOC BSA based melphalan dosing at 140 or 200mg/m2 per treating physician on Day -2
Study NCT05065528 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Magnesium
Description: Will receive symptomatic care (ondansetron 4mg and acetaminophen 500 mg each twice daily) along with 400 mg supplemental magnesium twice daily for 3 days
Study NCT05065528 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Will receive symptomatic care (ondansetron 4mg and acetaminophen 500 mg each twice daily) along with placebo pill
Study NCT06626958 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stress Ball
Description: Stress Ball app
Study NCT06685068 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GEN1286
Description: Specified dose on specified days
Study NCT06686238 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MITOVIT® Hypoxic Training System
Description: The EG (Experimental Group) will undergo a single session of IHHE (Intermittent Hypoxia-Hyperoxia Exposure) session using the MITOVIT® Hypoxic Training System (COMMIT GmbH, Salzgitter, Germany). They will breathe air with an oxygen concentration (FiO2) ranging from 10-14% for 5 minutes, followed by 3 minutes of rest in hyperoxia (FiO2 30-40%), for a total of 6 cycles. During the hypoxic phase, oxygen saturation will be maintained between 85-92%, while during the hyperoxic phase, it will be kept above 95%. This process is regulated by the device's AI. Participants will be asked to sit and breath normally in each exposure. An attendance checklist will be used to monitor compliance with the intervention
Study NCT06686238 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham MITOVIT® Hypoxic Training System
Description: The Sham Group (SG) will follow a single session protocol of 5 cycles of 6 minutes per session with an FiO2 of 21% using the MITOVIT® Hypoxic Training System (COMMIT GmbH, Salzgitter, Germany). Participants will be asked to sit and breath normally in each exposure. An attendance checklist will be used to monitor compliance with the placebo intervention.
Study NCT06099821 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib
Description: Regorafenib is a multi-target tyrosine kinase inhibitors and is one of the standard third-line therapy in mCRC
Study NCT06099821 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Apatinib is a novel, small molecule, selective vascular endothelial growth factor receptor-2 (VEGFR-2) tyrosine kinase inhibitor and is the second anti-angiogenic drug to be approved in China for the treatment of advanced or metastatic gastric cancer. It has been also reported to have anti-tumor efficacy in other kinds of digestive system cancers.
Study NCT04750629 — intervention group
Intervention type: DEVICE
Intervention: POC CoviDx™ Rapid Antigen Test
Description: All patients will have a nasal swab for CoviDx™ Rapid Antigen testing
Study NCT05492474 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cranial Point of Care Ultrasound
Description: Cranial ultrasound involves 2-dimensional B mode imaging of the brain parenchyma in the axial plane using a 1-2 MHz probe through the thin temporal bone. Upload of cPOCUS images will occur over DICOM® based Health Insurance Portability and Accountability Act (HIPAA) compliant platforms accessible via Cloud. Currently all handheld machines use Tricefy® or their own cloud based remote image access application.
Study NCT06510283 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taitacept
Description: Telitacicept will be subcutaneously injected at a dose of 240mg per week, lasting for at least 24 weeks.
Study NCT06631755 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Xience Skypoint stent over calcified coronary lesions
Description: Patients with Xience Skypoint stent implanted after OCT assesment of calcification
Study NCT06703385 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Instrument Assisted soft tissue mobilization
Description: The blade is a surgical instrument for soft tissue mobilization, made of 100% surgical stainless steel with 8 treatment planes and 2 treatment edges. It is used to locate muscle limitations and apply gentle strokes along the affected muscle, detecting changes in soft tissue consistency. The procedure is repeated three times a week for four weeks.
Study NCT06703385 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Suboccipital release
Description: The patient will lie in a relaxed supine position, with a therapist sitting on a chair. The therapist will apply pressure to the C2 area, holding it until a melting sensation is felt. The intervention time is 4 minutes. The patient will close both eyes during the Suboccipital release procedure to prevent eye movements affecting muscle tone. Interventions will be three times a week for four weeks.
Study NCT06703385 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional physical therapy program
Description: The patient is placed in a sitting position and a hot pack is applied to the back of the neck for 15 minutes. The therapist then performs active range of motion exercises for neck flexion, extension, rotation, and lateral flexion without resistance. They also perform stretching exercises for upper Trapezius muscle and suboccipital muscle. Strengthening exercises for neck muscles are performed through isometric exercises, such as side pending to right, side pending to left, extension, and flexion. The interventions are conducted three times, peer-wise, for four weeks. The treatment aims to improve neck flexibility and overall well-being.
Study NCT06703385 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional physical therapy program
Description: The patient is placed in a sitting position and a hot pack is applied to the back of the neck for 15 minutes. The therapist then performs active range of motion exercises for neck flexion, extension, rotation, and lateral flexion without resistance. They also perform stretching exercises for upper Trapezius muscle and suboccipital muscle. Strengthening exercises for neck muscles are performed through isometric exercises, such as side pending to right, side pending to left, extension, and flexion. The interventions are conducted three times, peer-wise, for four weeks. The treatment aims to improve neck flexibility and overall well-being.
Study NCT06704776 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: The medially pedicled IPFP flap group
Description: In the The medially pedicled IPFP flap group, the IPFP was exposed and separated, and the lateral side was left intact and the medial side was tipped to form a complete medially tipped IPFP flap, and the IPFP flap was clipped and draped over the medial side to avoid interference of the IPFP with the operative field. After successful implantation of the prosthesis, the IPFP was fixed with in situ sutures.
Study NCT06704776 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Complete IPFP removal group
Description: The entire IPFP was resected from below the patellar tendon prior to femoral preparation.
Study NCT06674902 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrolysis Percutaneous Therapeutic (EPTE)
Description: EPTE device (Ionclinics, Valencia, Spain)
Study NCT06709118 — intervention group
Intervention type: DEVICE
Intervention: fiberoptic
Description: Tracheal intubation was performed with different outer diameters of fiberoptic.
Study NCT05805345 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Delefilcon A toric soft contact lens
Description: Commercially available silicone hydrogel contact lens
Study NCT05805345 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Lehfilcon A toric soft contact lens
Description: Commercially available silicone hydrogel contact lens
Study NCT05805345 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Lotrafilcon B toric soft contact lens
Description: Commercially available silicone hydrogel contact lens
Study NCT05805345 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Verofilcon A toric soft contact lens
Description: Commercially available silicone hydrogel contact lens
Study NCT06467955 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnet System, DI Biofragmentable
Description: Anastomoses achieved by magnetic compression.
Study NCT06271356 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BC-Navigate
Description: BC-Navigate is a website/application to help guide women through care delivery during breast cancer treatment.
Study NCT06122415 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Plasma Amyloid Probability Score 2 (APS 2) score
Description: APS 2 score (combination of ptau217/nptau217 and Ab42/Ab40). The cut off will be predefined. The samples will be analysed prospectively every two weeks.
Study NCT06122415 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Plasma ptau217/nptau217
Description: The cut off will be predefined. The samples will be analysed prospectively every two weeks.
Study NCT06710379 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADRX-0405
Description: Antibody Drug Conjugate targeting STEAP1
Study NCT06709768 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Memory, Attention, and Problem Solving Skills for Persons with MS (MAPSS-MS)
Description: This is a pilot test of the MAPSS-MS intervention in a virtual delivery format.
Study NCT06122415 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Plasma ptau217
Description: The cut off will be predefined. The samples will be analysed prospectively every two weeks.
Study NCT06122415 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Plasma neurofilament light (NfL)
Description: The cut off will be predefined. The samples will be analysed prospectively every two weeks.
Study NCT06708780 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ex vivo Expanded Human Autologous Regulatory T Cells
Description: Peripheral blood component donation is used to collect Treg cells for ex vivo expansion, with technical guidance provided by the Center for Biotechnology Drug Development at the Shanghai Institute of Materia Medica, Chinese Academy of Sciences.
Study NCT06708780 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Routine Care
Description: Routine care is provided to all participants according to clinical guidelines for T1DM.
Study NCT06708780 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Routine Care
Description: Routine care is provided to all participants according to clinical guidelines for T1DM.
Study NCT06709040 — intervention group
Intervention type: DRUG
Intervention: Somapacitan
Description: Participants will be treated with commercially available somapacitan according to routine clinical practice at the discretion of the treating physician.
Study NCT06708481 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: P11-4, a self-assembling peptide
Description: rationally designed peptide, the monomers of which self-assemble into a biocompatible fibrillar scaffold that mimics the enamel matrix in response to particular environmental cues
Study NCT06708481 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: P11-4, a self-assembling peptide with flouride
Description: self assembling peptide with 500 ppm sodium fluoride
Study NCT06708481 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: resin infilteration
Description: Improvement of white spot lesions appearance by infiltration occurs due to a change in the refractive index since the refractive index of enamel (1.62-1.65) is different than that of air (1.00). Infiltration of the lesions with an infiltrate that has a refractive index of 1.52 is able to mask the lesion